Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

OBJECTIVE: To describe survival of patients with hepatic encephalopathy (HE), up to 5 years after initiation of rifaximin-α (RFX) treatment. DESIGN/METHOD: A retrospective, observational extension study within 9 National Health Service secondary/tertiary UK care centres. All patients had a clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Aspinall, Richard J, Hudson, Mark, Ryder, Stephen D, Richardson, Paul, Farrington, Elizabeth, Wright, Mark, Przemioslo, Robert T, Perez, Francisco, Kent, Melanie, Henrar, Roland, Hickey, Joe, Shawcross, Debbie L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Liver
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086718/
https://www.ncbi.nlm.nih.gov/pubmed/37056320
http://dx.doi.org/10.1136/flgastro-2022-102221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086718/
https://www.ncbi.nlm.nih.gov/pubmed/37056320
http://dx.doi.org/10.1136/flgastro-2022-102221

Ejemplares similares